Cancer Progress and Priorities: Lung Cancer

作者：Matthew B. Schabath, Michele L. Coté · 发表于：Cancer Epidemiology Biomarkers & Prevention · 年份：2019 · DOI：10.1158/1055-9965.epi-19-0221 · 被引用次数：1185 · 研究领域：Global Cancer Incidence and Screening、Lung Cancer Treatments and Mutations、Esophageal Cancer Research and Treatment

In the United States, lung cancer is the second most common diagnosed cancer and the leading cause of cancer-related death. Although tobacco smoking is the major risk factor accounting for 80% to 90% of all lung cancer diagnoses, there are numerous other risk factors that have been identified as casually associated with lung cancer etiology. However, there are few causally linked risk factors for lung cancer diagnosed among never smokers, which, if considered a unique reportable category, is the 11th most common cancer and the 7th leading cause of cancer-related death. Lung cancer survival has only marginally improved over the last several decades, but the availability of screening and early detection by low-dose CT and advances in targeted treatments and immunotherapy will likely decrease mortality rates and improve patient survival outcomes in the near future.Globally, lung cancer has been the most common diagnosed cancer for the last several decades (1, 2). In 2018, there was an estimated 2.1 million new lung cancer diagnoses accounting for 12% of the global cancer burden (1, 2). Among men, lung cancer remains the most common cancer diagnosis with approximately 1.37 million diagnoses in 2018, with the highest incidence rates in Micronesia (54.1 per 100,000), Polynesia (52.0 per 100,000), Central and Eastern Europe (49.3 per 100,000), and Eastern Asia (47.2 per 100,000). Among women, incidence rates are generally lower than men with approximately over 725,000 new lung cance...